JAMA (Journal of the American Medical Association)
Відкрити в Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
Показати більше📈 Аналітичний огляд Telegram-каналу JAMA (Journal of the American Medical Association)
Канал JAMA (Journal of the American Medical Association) (@jamaupdates) у мовному сегменті Англійська є активним учасником. На даний момент спільнота об'єднує 15 827 підписників, посідаючи 1 534 місце в категорії Медицина та 2 414 місце у регіоні США.
📊 Показники аудиторії та динаміка
З моменту свого створення невідомо, проект продемонстрував стрімке зростання, зібравши аудиторію у 15 827 підписників.
За останніми даними від 26 липня, 2026, канал демонструє стабільну активність. Хоча за останні 30 днів спостерігається зміна кількості учасників на 447, а за останні 24 години на 33, загальне охоплення залишається високим.
- Статус верифікації: Не верифікований
- Рівень залученості (ER): Середній показник залученості аудиторії становить 7.02%. Протягом перших 24 годин після публікації контент зазвичай збирає 2.38% реакцій від загальної кількості підписників.
- Охоплення публікацій: В середньому кожен допис отримує 1 111 переглядів. Протягом першої доби публікація в середньому набирає 376 переглядів.
- Реакції та взаємодія: Аудиторія активно підтримує контент: середня кількість реакцій на один пост – 1.
- Тематичні інтереси: Контент зосереджений навколо ключових тем, таких як patient, disease, treatment, drug, guideline.
📝 Опис та контентна політика
Автор описує ресурс як майданчик для висловлення суб'єктивної думки:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
Завдяки високій частоті оновлень (останні дані отримано 27 липня, 2026), канал підтримує актуальність та високий рівень охоплення публікацій. Аналітика показує, що аудиторія активно взаємодіє з контентом, що робить його важливою точкою впливу в категорії Медицина.
15 827
Підписники
+3324 години
+1197 днів
+44730 день
Архів дописів
Moving Beyond Legal Phobia to Medicolegal Advocacy in Neurology
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851971
This Viewpoint discusses neurologists writing letters on patients’ behalf for legal proceedings.
Gefurulimab and Generalized Myasthenia Gravis
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851972
This randomized clinical trial compares the novel dual-binding nanobody gefurulimab vs placebo for treating anti–acetylcholine receptor antibody–positive generalized myasthenia gravis.
First Effective Nanobody in Myasthenia Gravis Therapy
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851973
In generalized myasthenia gravis (gMG), a continuously increasing spectrum of immunomodulatory agents with different mechanisms of action have been studied, including T- and B-cell directed drugs and drugs acting on downstream antibody-metabolism, such as neonatal Fc receptor (FcRn) and complement inhibitors. Because of the particular pathogenic properties of anti–acetylcholine receptor antibody (AChR-Ab) of the IgG1 and IgG3 type, blocking of complement factor 5 (C5) has been established as a rapidly effective therapeutic principle in generalized AChR-Ab–positive MG during the last decade. Inhibition of complement factor 5 (C5) activation (and thereby cleavage of C5 into C5a and C5b) prevents from membrane attack complex mediated structural damage of the postsynaptic muscle end plate contributing to impaired neuromuscular transmission in AChR-Ab–positive gMG. Apart from already approved C5 inhibitors like eculizumab, ravulizumab, and zilucoplan, further agents directed against C5 but also against other complement factors have been developed. Gefurulimab (formerly ALXN1720), a bispecific nanobody, specifically targets C5 and also human serum albumin (HSA) by a C-terminal C5-binding heavy domain of heavy chain (VHH) connected to an N-terminal albumin-binding VHH via a flexible linker. Binding to HSA extends half-life time of gefurulimab by FcRn-mediated recycling.
Exercise and Aortic Stenosis
https://jamanetwork.com/journals/jamacardiology/fullarticle/2851755
The management of severe aortic stenosis (AS) is undergoing a fundamental transformation. For decades, intervention was generally deferred until symptom onset or overt left ventricular systolic dysfunction. This strategy reflected a rational clinical balance: procedural risk was substantial, symptom development signaled clinical decompensation, and watchful waiting appeared prudent. Today, that paradigm is increasingly challenged.
Road Traffic Noise and Risk of Parkinson Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851756
This cohort study evaluates the association between long-term exposure to road traffic noise and risk of Parkinson disease.
Error in Text
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851758
In the Images in Neurology titled “Aberrant Left-to-Right Fusion of the Oculomotor Nerve,” published on May 26, 2026, there was an error in the units of measure provided in the second sentence of the first paragraph. The sentence should have read, “On examination, the patient’s primary position revealed a 20° esotropia of the right eye and a 25° exotropia of the left eye, accompanied by mild ptosis and notable enophthalmos.” This article was corrected online.
Environmental Risk in Parkinson Disease—Bring the Noise
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851757
Parkinson disease (PD) affects over 11 million people worldwide and is among the fastest-growing causes of neurological death and disability. This trend highlights the critical need to identify and address modifiable risk factors of PD. Several environmental chemicals have been linked to PD risk, including pesticides, hydrocarbon solvents, and air pollutants. Living in areas with increased potential exposure to environmental toxicants—including farms, industrial sites, and golf courses—is also associated with PD. Given this mounting evidence, strategies to reduce the global burden of PD must focus on environmental risk factors.
Error in the Strengths and Limitations
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851759
In the Original Investigation titled “Amateur Soccer Heading and Acute Elevations in Blood-Based p-Tau217 and S100B,” published online on May 18, 2026, there was an error in the Strengths and Limitations section regarding a biomarker referred to as being lower in the exposed group. Biomarkers “S100B and NfL” have been changed to “S100B and BD-tau.” This article has been corrected online.
Clear Liquids, Safer Procedures
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2851435
To the Editor We read with interest the OCULUS randomized clinical trial by Ahmad and colleagues that evaluated the effects of continuing vs withholding glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (GLP-1/GIP RAs) before upper endoscopy. As the first such trial to our knowledge, it addressed a gap in evidence regarding periprocedural management of these agents, which has previously been guided mainly by observational data and expert opinion.
Practice Pattern and Outcome Differences in the ED by Physician Sex
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2851436
This cross-sectional study evaluates differences in test ordering and hospital admission rates between female and male physicians working in the Veterans Affairs system’s emergency departments.
From Initiation of Guideline-Directed Medical Therapy to Persistent Use in Heart Failure
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2851437
Clinical guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) should be treated with 4 classes of medications: renin-angiotensin system inhibitors, β-blockers, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter 2 inhibitors. Guideline-directed medical therapy (GDMT) is associated with improved survival and reduction in hospitalizations for heart failure and incremental benefit is observed with use of all 4 classes of drugs.
Clinician Moral Injury and Immigration Policy
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2851438
Since January 2025, this country has undertaken what is likely among the most expansive immigration enforcement agendas in modern US history. Immigration policy has focused on aggressive enforcement tactics rather than integration and immigrant well-being. This policy agenda and its enforcement have resulted in fear, isolation, and decreased health care utilization among those with immigrant backgrounds. Additionally, the provision of health care has been affected by policies allowing Immigration and Customs Enforcement (ICE) agents to enter previously protected locations including hospitals, and sharing data between the Centers for Medicare & Medicaid Services and Department of Homeland Security. A less well-known effect of the increased immigration enforcement is the harm experienced by those clinicians caring for immigrant populations, through moral injury and vicarious traumatization. This issue of JAMA Internal Medicine includes 2 articles exploring the moral injury experienced by clinicians caring for immigrant patients in the US during the recent, and ongoing, surge of immigration law enforcement action.
Physician Sex and Practice Pattern Differences in the Emergency Department
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2851439
There is a growing literature on physician sex differences in patient care and outcomes that largely favor female physicians. Studies in the primary care setting find, for example, that female physicians spend more time in direct and indirect patient care, use more patient-centered communication, and provide more evidence-based services, although the evidence is more mixed on the provision of low-value care. But one challenge of these studies is that it is difficult in the primary care setting to disentangle the effects of patient expectations, self-selection to their treating physician, and the dyadic interaction between patient and clinician on practice patterns and outcomes. Hospital-based studies that can leverage more random assignment of patients to physicians have found that patients treated by female physicians have better outcomes, such as lower mortality and hospital readmission rates, but beyond this, little is understood about how practice patterns differ by sex in the acute care setting.
Cessation of Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis—Clinical Trial of the Year
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851873
Can patients with multiple sclerosis (MS) safely discontinue their disease-modifying therapy, even after years of clinical stability? That is the question that was addressed by the DOT-MS trial, which is my pick for trial of the year in 2025.
Challenges Implementing Remote Patient Monitoring for Hypertension
https://jamanetwork.com/journals/jamacardiology/fullarticle/2851053
The recent article by Unlu et al highlights persistent patient engagement barriers to effective hypertension management. Unfortunately, their concerns on home blood pressure monitoring (HBPM) miss a critical opportunity to highlight potential for mitigating serious morbidity and mortality in a particular patient subgroup: pregnancy.
Device-Assisted and Modified Valsalva Maneuvers for Supraventricular Tachycardia
https://jamanetwork.com/journals/jamacardiology/fullarticle/2851054
To the Editor We read with great interest the Brief Report published by Huang et al, evaluating the performance of a device-assisted Valsalva maneuver compared with the standard maneuver for conversion of supraventricular tachycardia (SVT).
Reigniting the Effort to Prevent Premature Death and Extend Healthy Life Span
https://jamanetwork.com/journals/jamacardiology/fullarticle/2851055
This issue of JAMA Cardiology includes the latest of many substantial reports from the Global Burden of Disease Study regarding the trajectory of chronic disease in the US. The report’s overall storyline is not surprising: the underlying major risk factors for ischemic heart disease (IHD) are well known, and overall IHD mortality rates continue to drop. Reductions in risk due to improvements in blood pressure control and management of low-density lipoprotein (LDL) cholesterol levels likely explain much of the reduction in IHD risk since 1990. However, the rate of decrease has slowed since 2010, treatment effectiveness has plateaued, and progress remains inadequate.
Neurological Manifestations of Hantavirus Infection
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851731
This narrative review discusses the neurological complications of hantaviruses that, although rare, carry a high mortality rate, are typically secondary to ischemic injury or metabolic dysfunction, and can affect the peripheral or central nervous system.
Recommendations for Reporting on Potential Harms in Randomized Clinical Trials in JAMA Internal Medicine
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2851381
Randomized clinical trials, when rigorously conducted, offer the highest level of evidence to evaluate health care interventions. The value of a health care intervention depends on the benefits relative to the harms, which can be physical, psychological, or social. Published reports of randomized clinical trials uniformly focus on the benefits of the intervention being studied but often provide inadequate information regarding harms. There have been documented failures to report serious adverse events related to interventions, as well as discrepancies in harms reporting that arise from different approaches to monitoring, collecting, and classifying adverse events. Beyond these notable failures, there has been a general lack of adequate information on methods, analyses, and outcomes related to harms of interventions. As a result, there is a well-recognized need to improve reporting of harms in randomized clinical trials. The Consolidated Standards of Reporting Trials (CONSORT) Harms 2022 guideline provides standards for reporting harms, and select items related to harms were included in the revision of the main CONSORT 2025 guideline on reporting clinical trials. In this Editorial, we outline 3 key expectations for reporting harms in randomized clinical trials published in JAMA Internal Medicine.
Dementia Prevalence Trends in Latin America and the Caribbean
https://jamanetwork.com/journals/jamaneurology/fullarticle/2851645
This cross-sectional study examines trends in dementia prevalence over 2 decades at 5 sites across Latin America and the Caribbean.
